Lisa A. Michaels M.D.
Net Worth
Last updated:
What is Lisa A. Michaels M.D. net worth?
The estimated net worth of Dr. Lisa A. Michaels M.D. is at least $962,273 as of 12 Nov 2021. He owns shares worth $48,292 as insider, has earned $60,101 from insider trading and has received compensation worth at least $853,880 in Editas Medicine, Inc..
What is the salary of Lisa A. Michaels M.D.?
Dr. Lisa A. Michaels M.D. salary is $213,470 per year as Executive Vice President & Chief Medical Officer in Editas Medicine, Inc..
How old is Lisa A. Michaels M.D.?
Dr. Lisa A. Michaels M.D. is 60 years old, born in 1965.
What stocks does Lisa A. Michaels M.D. currently own?
As insider, Dr. Lisa A. Michaels M.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | Executive Vice President & Chief Medical Officer | 18,432 | $2.62 | $48,292 |
What does Editas Medicine, Inc. do?
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Lisa A. Michaels M.D. insider trading
Editas Medicine, Inc.
Dr. Lisa A. Michaels M.D. has made only one insider trade in 2021, according to the Form 4 filled with the SEC. He sold 1,568 units of EDIT stock worth $60,101 on 12 Nov 2021.
As of 12 Nov 2021 he still owns at least 18,432 units of EDIT stock.
Editas Medicine key executives
Editas Medicine, Inc. executives and other stock owners filed with the SEC:
- Dr. Lisa A. Michaels M.D. (60) Executive Vice President & Chief Medical Officer
- Mr. James C. Mullen (66) Chairman, Pres & Chief Executive Officer
- Ms. Michelle Robertson (58) Chief Financial Officer, Principal Accounting Officer, Treasurer & Assistant Sec.